Respert: Glad you agree my friend. CYDY's recent transfer of LL manufacturing technology, without identifying the recipient, and under circumstances where a drug manufacturing competitor of Samsung would be unlikely to extend credit to CYDY, leaves only drug companies with in house manufacturing capabilities as viable recipients of the technology -- and that type of a transfer can only mean BO or partnership, cloaked for the time being in a NDA.

This situation is probably the most encouraging development for CYDY shareholders since we were optimistically anticipating the covid trial results.